Daniel C. Brennan, MD | Washington University | St. Louis, MO

This study is for participants who have received up to three islet cell infusions as a previous participant in the ITN005CT study.  Study participants will receive a maintenance immunosuppressive treatment regimen consisting of a combination of orally administered drugs (tacrolimus (Prograf®), sirolimus (Rapamune®), mycophenolate mofetil (MMF, Cellcept®), and/or mycophenolic acid (MPA, Myfortic®).) This protocol provides a way to supply these immunosuppressive medications to subjects whose islets continue to function and make C-peptide.